Treosulfan
 | |
| Systematic (IUPAC) name | |
|---|---|
|
(2S,3S)-2,3-Dihydroxybutane-1,4-diyl dimethanesulfonate | |
| Clinical data | |
| AHFS/Drugs.com | International Drug Names |
| Routes of administration | Oral, IV |
| Identifiers | |
| CAS Number |
299-75-2  |
| ATC code | L01AB02 |
| PubChem | CID 9296 |
| UNII |
CO61ER3EPI  |
| Synonyms | 1,2,3,4-Butanetetrol, 1,4-dimethanesulfonate, Threitol 1,4-dimethanesulfonate, Threitol 1,4-bismethanesulfonate; L-Threitol 1,4-bis(methanesulfonate); Ovastat; Threosulphan; Treosulphan; Tresulfan |
| Chemical data | |
| Formula | C6H14O8S2 |
| Molar mass | 278.30056 g·mol−1 |
| Physical data | |
| Melting point | 101.5 to 105 °C (214.7 to 221.0 °F) |
| (what is this?) (verify) | |
Treosulfan is a substance that is being studied in the treatment of cancer.[1] It belongs to the family of drugs called alkylating agents. It has been used mainly as a substitute of busulfan in frail patients, as the side effects and toxicity are supposedly less severe.
References
- ↑ Schmittel A, Schmidt-Hieber M, Martus P, et al. (December 2006). "A randomized phase II trial of gemcitabine plus treosulfan versus treosulfan alone in patients with metastatic uveal melanoma". Ann. Oncol. 17 (12): 1826–9. doi:10.1093/annonc/mdl309. PMID 16971664.
External links
- Treosulfan entry in the public domain NCI Dictionary of Cancer Terms
This article incorporates public domain material from the U.S. National Cancer Institute document "Dictionary of Cancer Terms".
| ||||||||||||||||||||||||||||||||||||||
This article is issued from Wikipedia - version of the Wednesday, September 02, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.